For Clinics

B2B resources and operational guidance for ketamine and psychedelic clinic owners.

Congress Pushes To Turn Trump’s Psychedelic Therapy Order Into Law

A new bipartisan bill would take President Trump’s psychedelic therapy order and try to make it harder to undo.

Read More

The American Legion Just Backed a Specific Psychedelics Bill, Not Just the Idea

The American Legion adopted a resolution backing psychedelic therapy for veterans. It endorses S.4220, which would build a VA office

Read More

Three Psychedelic Companies Analysts Say Could Be Acquired Next

The Deal That Changed the Temperature Eli Lilly agreed in July to pay up to $3.8 billion for AtaiBeckley. That

Read More

How We Saved One Ketamine Clinic Network $38,000 a Year on Medical Supplies

We just negotiated GPO-level medical supply pricing exclusively for Healing Health Alliance members. The proof: one HHA member ketamine practice

Read More

Three Infusions in Twelve Weeks: A Toronto Pain Trial Ran a Very Different Protocol

A Toronto trial paired ketamine with structured therapy for chronic nerve pain. It used three infusions over twelve weeks, not

Read More

FDA Finalizes Psychedelic Trial Guidance, Then Opens A Bigger Federal Conversation

The FDA finalized its first formal guidance for studying psychedelic drugs. The document sets the ground rules for research into

Read More

The Money Behind the MDMA Resubmission Came From a SpaceX Director

The WSJ reported that a SpaceX director gave $25 million to recapitalize the company behind MDMA-assisted therapy. That explains a

Read More

Psychedelic Trials Are Going Intravenous. Ketamine Clinics Already Have That Room

A new trial of intravenous psilocin points to where psychedelic delivery is heading. Ketamine clinics already have the infusion rooms

Read More

Psychedelic Trials Are Showing Big Results. The Methods Behind Them Are Getting a Closer Look

Clinical Trial Vanguard recently examined a tension that sits at the center of psychedelic research right now.

Read More

Oregon Tracks Psilocybin Safety for Three Days. The New Data Found Problems at Three Months

A JAMA Network Open study followed 346 people through Oregon's licensed psilocybin program. The adverse events showed up long after

Read More

Explore Psychedelic Therapy Regions